Annick Desjardins

15.7k total citations · 4 hit papers
247 papers, 10.0k citations indexed

About

Annick Desjardins is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Annick Desjardins has authored 247 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Genetics, 73 papers in Pulmonary and Respiratory Medicine and 67 papers in Oncology. Recurrent topics in Annick Desjardins's work include Glioma Diagnosis and Treatment (173 papers), Brain Metastases and Treatment (59 papers) and Cancer Research and Treatments (31 papers). Annick Desjardins is often cited by papers focused on Glioma Diagnosis and Treatment (173 papers), Brain Metastases and Treatment (59 papers) and Cancer Research and Treatments (31 papers). Annick Desjardins collaborates with scholars based in United States, Canada and Thailand. Annick Desjardins's co-authors include Henry S. Friedman, James J. Vredenburgh, David A. Reardon, James E. Herndon, Allan H. Friedman, John H. Sampson, Jeremy N. Rich, Darell D. Bigner, Sridharan Gururangan and Jennifer A. Quinn and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Annick Desjardins

228 papers receiving 9.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology profile →
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

2007 815 citations James J. Vredenburgh, Annick Desjardins et al. Clinical Cancer Research profile →
Recurrent Glioblastoma Treated with Recombinant Poliovirus

2018 582 citations Annick Desjardins, Matthias Gromeier et al. profile →
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

2015 410 citations Duane A. Mitchell, Kristen A. Batich et al. profile →

Peers

Annick Desjardins

GENET

ONCOL

PRM

Peter Hau Germany

Antonio Omuro United States

Ryo Nishikawa Japan

Ian F. Parney United States

Howard Colman United States

Erik P. Sulman United States

Daniel P. Cahill United States

Burt Nabors United States

Marie‐France Hamou Switzerland

W.K. Alfred Yung United States

Peter Hau Germany

Annick Desjardins

6.9k ×1.1

GENET

5.1k ×1.6

2.8k ×1.0

ONCOL

2.2k ×1.0

PRM

3.2k ×1.5

Citations per year, relative to Annick Desjardins Annick Desjardins (= 1×) peers Peter Hau

Countries citing papers authored by Annick Desjardins

Since Specialization

Citations

This map shows the geographic impact of Annick Desjardins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annick Desjardins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annick Desjardins more than expected).

Fields of papers citing papers by Annick Desjardins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annick Desjardins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annick Desjardins. The network helps show where Annick Desjardins may publish in the future.

Co-authorship network of co-authors of Annick Desjardins

This figure shows the co-authorship network connecting the top 25 collaborators of Annick Desjardins. A scholar is included among the top collaborators of Annick Desjardins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annick Desjardins. Annick Desjardins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Johnson, Margaret, Kristen A. Batich, Justin Low, et al.. (2024). NIMG-77. MRI PHENOMENON OF PUNCTATE ENHANCING LESIONS IN PATIENTS TREATED WITH IDH INHIBITORS. Neuro-Oncology. 26(Supplement_8). viii213–viii213.

Thompson, Eric M., David M. Ashley, Pamela K. Norberg, et al.. (2024). Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.. Journal of Clinical Oncology. 42(16_suppl). 2039–2039. 4 indexed citations

Brown, Michael C., Georgia M. Beasley, Yuanfan Yang, et al.. (2023). Intratumor childhood vaccine-specific CD4⁺ T-cell recall coordinates antitumor CD8⁺ T cells and eosinophils. Journal for ImmunoTherapy of Cancer. 11(4). e006463–e006463. 4 indexed citations

Peters, Katherine B., Daniel Landi, Gloria Broadwater, et al.. (2023). Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma. Neuro-Oncology Practice. 11(2). 199–204. 11 indexed citations

Kang, Jennifer, Christa B. Swisher, James E. Herndon, et al.. (2021). Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis. CNS Oncology. 10(3). CNS77–CNS77. 3 indexed citations

Randazzo, Dina, Frances McSherry, James E. Herndon, et al.. (2021). Spiritual well-being and its association with health-related quality of life in primary brain tumor patients. Neuro-Oncology Practice. 8(3). 299–309. 15 indexed citations

McSherry, Frances, et al.. (2019). Second primary cancers in long-term survivors of glioblastoma. Neuro-Oncology Practice. 6(5). 386–391. 5 indexed citations

Desjardins, Annick, James E. Herndon, Frances McSherry, et al.. (2019). Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice. Health Science Reports. 2(4). e114–e114. 11 indexed citations

Johnson, Margaret, John P. Kirkpatrick, Annick Desjardins, et al.. (2019). The role of chemotherapy in the treatment of central neurocytoma. CNS Oncology. 8(3). CNS41–CNS41. 12 indexed citations

10.

Randazzo, Dina, Frances McSherry, James E. Herndon, et al.. (2019). Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population. Complementary Therapies in Clinical Practice. 36. 43–48. 8 indexed citations

11.

Dunn‐Pirio, Anastasie, Katherine B. Peters, Annick Desjardins, et al.. (2017). Tumor stem cell RNA-loaded dendritic cell vaccine for recurrent glioblastoma: a phase 1 trial (S41.004). Neurology. 88(16_supplement). 4 indexed citations

12.

Sampson, John H., Robert J. Schmittling, Gary E. Archer, et al.. (2012). A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma. PLoS ONE. 7(2). e31046–e31046. 91 indexed citations

13.

Reardon, David A., April Coan, James E. Herndon, et al.. (2011). Exercise Behavior, Functional Capacity, and Survival in Adults With Malignant Recurrent Glioma. Journal of Clinical Oncology. 29(21). 2918–2923. 94 indexed citations

14.

Vredenburgh, James J., Annick Desjardins, David A. Reardon, et al.. (2011). The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma. Clinical Cancer Research. 17(12). 4119–4124. 112 indexed citations

15.

Reardon, David A., Annick Desjardins, Katherine B. Peters, et al.. (2011). Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 117(23). 5351–5358. 69 indexed citations

16.

Ding, Dale, Ankit I. Mehta, Ian Crocker, et al.. (2011). A Novel Method for Volumetric MRI Response Assessment of Enhancing Brain Tumors. PLoS ONE. 6(1). e16031–e16031. 40 indexed citations

17.

Reardon, David A., Merrill J. Egorin, Annick Desjardins, et al.. (2009). Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 115(10). 2188–2198. 69 indexed citations

18.

Desjardins, Annick, David A. Reardon, James E. Herndon, et al.. (2008). Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas. Clinical Cancer Research. 14(21). 7068–7073. 130 indexed citations

19.

Guiu, Séverine, Sophie Taillibert, Olivier Chinot, et al.. (2008). Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef. Revue Neurologique. 164(6-7). 588–594. 39 indexed citations

20.

Sathornsumetee, Sith, David A. Reardon, Annick Desjardins, et al.. (2007). Molecularly targeted therapy for malignant glioma. Cancer. 110(1). 13–24. 250 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact